Log In
Print this Print this

Radretumab (L19-131-I)

  Manage Alerts
Collapse Summary General Information
Company Philogen S.p.A.
DescriptionRadiolabeled version of L19, a recombinant human antibody against the EDB domain of fibronectin
Molecular Target
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase II
Standard IndicationHodgkin's disease
Indication DetailsTreat Hodgkin's lymphoma
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today